Sosei Heptares

Showing 7 posts of 7 posts found.


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

September 12, 2023
Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …


Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial

August 10, 2023
Research and Development Cancer Research UK, Oncology, Sosei Heptares, clinical trial, immunology

Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed in their phase 1/2a clinical …


Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023
Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …


Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels

February 1, 2021
Sales and Marketing Sosei Heptares

Sosei Heptares has announced it will collaborate with Metrion Biosciences, a specialist ion channel CRO and drug discovery company, to …


Sosei Heptares and PharmEnable collaborate on neurological drug research

January 12, 2021
Manufacturing and Production PharmEnable, Sosei Heptares

Sosei Group Corporation and PharmEnable, a UK drug discovery company, have joined forces to apply their respective technologies to drive …

Sosei Heptares to regain rights to muscarinic agonist programmes

January 5, 2021
Manufacturing and Production Sosei Heptares

Biopharmaceutical group Sosei Heptares has announced it is to regain the worldwide rights to its muscarinic agonist programmes, after they …

Takeda signs deal with Sosei Heptares worth $1.2 billion

August 6, 2019
Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei

Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets. The …

Latest content